Relmada Therapeutics (RLMD) Stock Price, News & Analysis

Company Overview

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Key Stats

• Today's Range: $0.36 to $0.40
• 50-Day Range: $0.35 to $3.30
• 52-Week Range: $0.34 to $7.22
• Volume: 208,625 shs
• Average Volume: 975,351 shs
• Market Capitalization: $11.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.25
• Consensus Rating: Hold

Relmada Therapeutics Stock Analysis - MarketRank™

Relmada Therapeutics scored higher than 81% of companies evaluated by MarketBeat, and ranked 214th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Relmada Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Relmada Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Relmada Therapeutics are expected to grow in the coming year, from ($2.73) to ($0.63) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Relmada Therapeutics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Relmada Therapeutics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Relmada Therapeutics has a P/B Ratio of 0.13. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.47% of the outstanding shares of Relmada Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Relmada Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Relmada Therapeutics has recently decreased by 7.30%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Relmada Therapeutics does not currently pay a dividend.

Dividend Growth

Relmada Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.45

Percentage of Shares Shorted

5.47% of the outstanding shares of Relmada Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Relmada Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Relmada Therapeutics has recently decreased by 7.30%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

MarketBeat Follows

Only 2 people have added Relmada Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Relmada Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.00% of the stock of Relmada Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

45.24% of the stock of Relmada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RLMD Stock Analysis - Frequently Asked Questions

How have RLMD shares performed this year?

Relmada Therapeutics' stock was trading at $0.52 at the beginning of 2025. Since then, RLMD stock has decreased by 28.1% and is now trading at $0.3738.
View the best growth stocks for 2025 here.

How were Relmada Therapeutics' earnings last quarter?

Relmada Therapeutics, Inc. (NASDAQ:RLMD) released its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.24.

How do I buy shares of Relmada Therapeutics?

Shares of RLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Relmada Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Relmada Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), ServiceNow (NOW), General Electric (GE) and Adobe (ADBE).

Company Calendar

• Last Earnings: 8/07/2024
• Today: 1/20/2025
• Next Earnings (Estimated): 3/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RLMD
• CUSIP: N/A
• CIK: 1553643
• Web: www.relmada.com
• Phone: (786) 629-1376
• Fax: N/A
• Employees: 10
• Year Founded: 2004

Price Target and Rating

• Average Stock Price Target: $4.25
• High Stock Price Target: $13.00
• Low Stock Price Target: $1.00
• Potential Upside/Downside: +1,037.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.87)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-98,790,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -129.80%
• Return on Assets: -112.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.89
• Quick Ratio: 6.89

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.84 per share
• Price / Book: 0.13

Miscellaneous

• Outstanding Shares: 30,170,000
• Free Float: 24,743,000
• Market Cap: $11.28 million
• Optionable: Optionable
• Beta: 0.51